A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus

NCT05123586 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

85

Enrollment

INDUSTRY

Sponsor class

Stopped Study terminated due to lack of efficacy

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG: LY3361237
DRUG: Placebo

Sponsor

Eli Lilly and Company